ReviewCurrent medical science2020
Strategies for Precise Engineering and Conjugation of Antibody Targeted-nanoparticles for Cancer Therapy.
Review in Current medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 16 citations in OpenAlex.
- Synthesis, characterization, and anticancer evaluation ofToxicology reports · 2026Article
- Fabrication and Functional Modification Strategies of Squid Ink-Derived Nanoparticles: From Natural Melanin to Multifunctional Biomaterials.Marine drugs · 2026Review
- Targeted siRNA Delivery Using Cetuximab-Conjugated Starch for Epidermal Growth Factor Receptor-Driven Head and Neck Squamous Cell Carcinoma.Small science · 2025Article
- The Dopaminergic and Anti-Neuroinflammatory Properties of Functionalized Nanoliposomes Containing Levodopa and Ibuprofen and Conjugated with Anti-Alpha-Synuclein Aptamer.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Overcoming delivery barriers in immunotherapy for glioblastoma.Drug delivery and translational research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improvements in the diagnosis and treatment of cancer are urgently needed for use in nanotechnology. Nanoparticles (NPs) can reduce the side effects of traditional chemotherapy by sustained release of loaded drugs and increase therapeutic efficiency. NPs can also enhance endothelial permeation retention by size effect and its accumulation in tumor cells through passive targeting. Furthermore, it is critical to treat cancer with a controlled targeted drug which can be specifically delivered into tumor cells and released there, resulting in a targeted therapy to eradicate tumor cells while sparing normal cells. To this end, antibody-mediated targeting therapy has been developed, but imperfections in antibodies (Abs) limit this therapy. Therefore, the combination of NPs and Abs has been highly valued in recent years, because conjugating special Abs on the surface of NPs can increase targeting efficiency, enabling selective delivery of anti-cancer drugs to tumor cells. In this mini-review, we would like to enumerate the strategies for the conjugation of Abs to the surface of the NPs as well as the precise engineering of targeted NPs. The application of targeting antibody fragments in this drug delivery system will also be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.